ArticleThe Journal of veterinary medical science2020
A comparison of two commercially available porcine reproductive and respiratory syndrome virus (PRRSV) modified-live virus vaccines analyzing the growth performance in 1-day-old vaccinated swine located on endemic farms co-circulating PRRSV-1 and PRRSV-2.
Article in The Journal of veterinary medical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- A countrywide survey of PRRS indicates widespread seroprevalence in India with age of the pig and zone as significant risk factors.Virusdisease · 2025Article
- Field Investigation Evaluating the Efficacy of Porcine Reproductive and Respiratory Syndrome Virus Type 2 (PRRSV-2) Modified Live Vaccines in Nursery Pigs Exposed to Multiple Heterologous PRRSV Strains.Animals : an open access journal from MDPI · 2025Article
- Molecular Characteristics and Pathogenicity of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) 1 in Taiwan during 2019-2020.Life (Basel, Switzerland) · 2023Article
- Testable Candidate Immune Correlates of Protection for Porcine Reproductive and Respiratory Syndrome Virus Vaccination.Vaccines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to compare the efficacy of a porcine reproductive and respiratory syndrome virus (PRRSV)-1 and PRRSV-2 modified-live virus (MLV) vaccines when administered at 1 day of age under field conditions. The piglets elicited anti-PRRSV antibodies at 1 day of age even in the presence of maternally derived antibodies. The number of PRRSV-2 genomic copies in the sera of pigs from the PRRSV-2 MLV-vaccinated pigs was significantly (P<0.05) lower when compared to PRRSV-1 MLV-vaccinated pigs. The average daily gain in PRRSV-2 MLV-vaccinated pigs was significantly (P<0.05) higher when compared to both PRRSV-1 MLV-vaccinated and unvaccinated pigs. This study demonstrated that vaccination as early as 1 day of age was effective against PRRSV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.